Antidepressants and allergy medication are both widely used in the UK, and many people find themselves taking both at the same time. Understanding how these drug classes can interact is essential for safe, effective treatment. Some combinations — particularly older antihistamines with tricyclic antidepressants or MAOIs — carry meaningful risks, including excessive sedation, anticholinergic effects, and potentially serious cardiac concerns such as QT-interval prolongation. This article explains the key interactions to be aware of, which combinations require the most caution, and how to manage allergies safely whilst taking antidepressants, in line with NHS, NICE, and MHRA guidance.

How Antidepressants and Allergy Medication Can Interact

Antidepressants and allergy medications can interact pharmacokinetically via shared cytochrome P450 enzymes, and pharmacodynamically through additive sedation, anticholinergic effects, or QT-interval prolongation.

When taking antidepressants alongside allergy medication, it is important to understand that both types of drug can act on overlapping systems in the body — particularly the central nervous system (CNS) and certain neurotransmitter pathways. Drug interactions can occur in two main ways: pharmacokinetic interactions, where one drug affects how the body absorbs, metabolises, or eliminates another; and pharmacodynamic interactions, where two drugs produce additive or opposing effects on the same biological target.

Some antidepressants — including tricyclic antidepressants (TCAs) such as amitriptyline, and certain selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine — are metabolised by liver enzymes known as cytochrome P450 enzymes (particularly CYP2D6 and CYP3A4). Some antihistamines share these metabolic pathways; for example, chlorphenamine and diphenhydramine are metabolised partly via CYP2D6, and loratadine via CYP3A4. Taking these together may alter plasma concentrations of one or both drugs, potentially increasing the risk of side effects or reducing therapeutic efficacy. It is worth noting that other antihistamines — such as cetirizine and fexofenadine — are minimally metabolised by cytochrome P450 enzymes and are therefore less likely to be affected in this way.

Experiencing these side effects? our pharmacists can help you navigate them →

Additionally, both older (first-generation) antihistamines and some antidepressants have anticholinergic properties — meaning they block the neurotransmitter acetylcholine. When combined, this effect can be amplified, leading to symptoms such as dry mouth, blurred vision, urinary retention, constipation, and confusion, particularly in older people.

A further pharmacodynamic concern is QT-interval prolongation. Certain antidepressants — notably citalopram and escitalopram (subject to MHRA safety guidance), as well as TCAs — can prolong the QT interval on an electrocardiogram. Some antihistamines, including hydroxyzine, promethazine, and diphenhydramine, carry a similar risk. Combining drugs that prolong the QT interval increases the risk of serious cardiac arrhythmias, including Torsade de Pointes. Patients and clinicians should check the NICE BNF and individual Summary of Product Characteristics (SmPC) for specific combinations.

If you experience drowsiness when taking allergy medication alongside an antidepressant, you should avoid alcohol, as this can further increase sedation, and you should not drive or operate machinery until you know how the combination affects you. Understanding these mechanisms is the first step in making safe, informed choices about allergy management whilst on antidepressant therapy.

Which Combinations Are Most Likely to Cause Problems

The highest-risk combinations involve TCAs or MAOIs with first-generation antihistamines or decongestants; MAOIs must never be taken with pseudoephedrine or phenylephrine due to the risk of hypertensive crisis.

Certain pairings of antidepressants and allergy medications carry a higher risk of clinically significant interactions and warrant particular caution. The most concerning combinations generally involve:

• Tricyclic antidepressants (TCAs) — such as amitriptyline, dosulepin, or clomipramine — combined with first-generation antihistamines (e.g., chlorphenamine or promethazine). Both drug classes have strong anticholinergic and sedative properties, and their combination can cause pronounced drowsiness, cognitive impairment, and an increased risk of falls, especially in older people. TCAs also prolong the QT interval; combining them with antihistamines that share this property (such as hydroxyzine, promethazine, or diphenhydramine) further increases cardiac risk.

• MAOIs (monoamine oxidase inhibitors) — such as phenelzine or tranylcypromine — combined with certain antihistamines or decongestants. MAOIs carry a high risk of serious interactions with a wide range of medications. In particular, patients taking MAOIs must not use products containing pseudoephedrine or phenylephrine — decongestants found in many over-the-counter combination 'hay fever' and 'cold and flu' remedies — as this combination can cause a potentially life-threatening hypertensive crisis. This restriction applies during MAOI treatment and for at least 14 days after stopping. Patients on MAOIs should not take any new medication, including over-the-counter allergy treatments, without explicit medical advice.

• SSRIs such as fluoxetine or paroxetine — which are potent inhibitors of CYP2D6 — may increase the plasma levels or effects of antihistamines metabolised by this enzyme, such as chlorphenamine and diphenhydramine. The clinical significance varies between individuals and drug combinations; patients should check the NICE BNF or consult a pharmacist or prescriber for specific guidance. Additionally, SSRIs such as citalopram and escitalopram are associated with QT-interval prolongation (see MHRA Drug Safety Updates), and combining these with QT-prolonging antihistamines warrants careful consideration and, where appropriate, ECG monitoring.

It is also worth noting that some antidepressants, such as mirtazapine, already possess antihistamine activity as part of their pharmacological profile. Adding an additional antihistamine on top of mirtazapine may therefore produce excessive sedation. Patients should always disclose their full medication list — including over-the-counter products and combination remedies — to their GP or pharmacist before starting any new allergy treatment.

Antihistamines to Use With Caution on Antidepressants

First-generation antihistamines (chlorphenamine, promethazine, diphenhydramine, hydroxyzine) carry the greatest risk alongside antidepressants; second-generation options such as fexofenadine are generally safer.

Antihistamines are broadly divided into two generations, and the distinction is highly relevant when considering their safety alongside antidepressants.

First-generation antihistamines — including chlorphenamine (Piriton), promethazine (Phenergan), and diphenhydramine — readily cross the blood-brain barrier and produce significant sedation and anticholinergic effects. These properties make them particularly problematic when combined with antidepressants that share similar mechanisms, such as TCAs or mirtazapine. The risks include:

• Excessive drowsiness and impaired concentration

• Increased anticholinergic burden (dry mouth, constipation, urinary retention)

• Cognitive impairment and confusion, particularly in older people

• Heightened risk of falls and accidents

• Additive QT-interval prolongation (particularly with promethazine, diphenhydramine, and hydroxyzine when combined with TCAs, citalopram, or escitalopram)

Hydroxyzine (available on prescription in the UK) deserves particular mention. The MHRA has issued safety guidance highlighting its risk of QT-interval prolongation and Torsade de Pointes. It should be used at the lowest effective dose, avoided in older people where possible, and used with caution alongside other QT-prolonging drugs, including certain antidepressants. Prescribers and patients should consult the SmPC and NICE BNF before combining hydroxyzine with antidepressants.

Second-generation antihistamines — such as cetirizine, loratadine, and fexofenadine — are generally considered safer because they are less sedating and have minimal anticholinergic activity. However, they are not entirely without risk. Cetirizine and levocetirizine can still cause drowsiness in some individuals, and their combination with CNS-depressant antidepressants may amplify this effect. Loratadine is less sedating than cetirizine for most people. Fexofenadine is generally regarded as the least sedating option and does not significantly inhibit or induce cytochrome P450 enzymes, making it less likely to interfere with antidepressant metabolism.

Not sure if this is normal? chat with one of our pharmacists →

Regardless of which antihistamine is used, patients should avoid alcohol and not drive or operate machinery if they experience drowsiness. Patients should read product information carefully and consult a pharmacist if they are unsure whether a particular antihistamine is appropriate given their antidepressant regimen.

Safer Allergy Treatment Options for People on Antidepressants

Non-sedating antihistamines (loratadine, fexofenadine) and intranasal corticosteroid sprays are the preferred, lower-risk allergy treatments for people taking antidepressants.

For people managing allergic conditions whilst taking antidepressants, there are several treatment strategies that are generally considered lower risk, though individual circumstances will always vary.

Non-sedating second-generation antihistamines remain the first-line recommendation for most allergic conditions, including hay fever and urticaria. Loratadine and fexofenadine are frequently cited as preferable options due to their low sedation profiles and limited interaction potential. NICE CKS guidance on allergic rhinitis supports the use of non-sedating antihistamines as initial therapy, alongside intranasal corticosteroids for more persistent or moderate-to-severe symptoms. Fexofenadine is available as a 120 mg pharmacy medicine for hay fever; the 180 mg strength is typically available on prescription only — a pharmacist can advise on the most appropriate option.

Intranasal corticosteroid sprays act locally within the nasal passages and have minimal systemic absorption, making them a safe and effective option for allergic rhinitis with no clinically meaningful interaction with antidepressants. In the UK, beclometasone, fluticasone propionate, and mometasone nasal sprays are all available as pharmacy medicines (without a prescription) for adults and adolescents meeting the relevant criteria; some strengths and formulations remain prescription-only. A pharmacist can advise on which products are available over the counter. Similarly, sodium cromoglicate eye drops can be used for allergic conjunctivitis with a very low risk of systemic interaction.

Non-pharmacological measures should not be overlooked. Saline nasal irrigation, allergen avoidance (such as checking pollen forecasts, wearing wraparound sunglasses, and showering after being outdoors), and keeping windows closed during high-pollen periods can meaningfully reduce symptom burden and the need for medication.

For skin-related allergic reactions such as eczema or contact dermatitis, topical corticosteroids and emollients are appropriate first-line treatments that carry no significant interaction risk with antidepressants. Where allergen immunotherapy is being considered for conditions such as severe hay fever or insect venom allergy, this should be managed by a specialist, with full disclosure of all current medications. In all cases, the goal is to identify the lowest-risk, most effective treatment that supports both physical and mental wellbeing.

When to Speak to Your GP or Pharmacist

Always consult a GP or pharmacist before starting any new allergy medication whilst on an antidepressant; seek urgent medical attention for palpitations, chest pain, fainting, or signs of anaphylaxis.

Knowing when to seek professional advice is an essential part of managing antidepressants and allergy medication safely. As a general principle, you should always consult your GP or pharmacist before starting any new allergy medication — including products available over the counter — if you are currently taking an antidepressant. This applies even to treatments that may seem straightforward, as interactions can be subtle and not immediately obvious.

If you experience a severe allergic reaction (anaphylaxis) — including difficulty breathing, swelling of the throat or tongue, or collapse — call 999 immediately or go to your nearest emergency department. This is a medical emergency.

You should also seek prompt advice from your GP or pharmacist if you experience any of the following after combining allergy medication with your antidepressant:

• Unusual or excessive drowsiness or difficulty staying awake

• Confusion, memory problems, or difficulty concentrating

• A rapid, irregular, or pounding heartbeat (palpitations), chest pain, or fainting — seek urgent medical attention for these symptoms

• Difficulty passing urine or significant constipation

• Worsening of mood, anxiety, or other mental health symptoms

• Any new or unexplained symptoms that coincide with starting allergy treatment

If you are concerned about a possible interaction with your antidepressant, do not stop taking your antidepressant abruptly without speaking to your prescriber first, as this can cause withdrawal effects and other complications.

Pharmacists are highly trained in drug interactions and are an accessible first point of contact — many community pharmacies offer private consultation services. If you are unsure whether a product is safe, show the pharmacist your full medication list, including any supplements or herbal remedies, as some (such as St John's Wort) can interact significantly with antidepressants.

If you are taking an MAOI or have a complex medication regimen, it is strongly advisable to speak to your GP before purchasing any allergy treatment, rather than relying solely on product labelling, which may not capture all relevant interactions.

If you think you have experienced a side effect from a medicine — including a suspected interaction — you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps the MHRA monitor the safety of medicines in the UK.

NHS and UK Guidance on Managing Allergies Alongside Mental Health Medication

NICE CKS, BSACI, and MHRA guidance supports a stepwise approach to allergy treatment in patients on antidepressants, prioritising non-sedating antihistamines and intranasal corticosteroids as first-line options.

The NHS and relevant regulatory bodies in the UK provide a framework for managing allergies safely, including in people taking mental health medications. NICE CKS (Clinical Knowledge Summaries) on Allergic Rhinitis recommends a stepwise approach to treatment, beginning with non-sedating antihistamines and intranasal corticosteroids, and escalating to specialist referral where symptoms are poorly controlled. The British Society for Allergy and Clinical Immunology (BSACI) also publishes UK-specific guidance on the management of allergic rhinitis, including pharmacotherapy recommendations. These recommendations remain applicable to patients on antidepressants, with the additional consideration of interaction risk.

The Medicines and Healthcare products Regulatory Agency (MHRA) periodically issues Drug Safety Updates regarding important interaction and safety signals. Relevant updates include guidance on QT-interval prolongation with citalopram and escitalopram, and on the cardiac risks associated with hydroxyzine. Healthcare professionals and informed patients are encouraged to consult the NICE BNF (available at bnf.nice.org.uk) for up-to-date interaction data and individual drug monographs. The BNF provides detailed interaction information for specific drug combinations and is an invaluable resource for both clinicians and patients.

The NHS also signposts patients to NHS 111 for urgent medication queries outside of GP hours, and the NHS website provides accessible information on common allergy treatments, including advice on sedation, driving, and alcohol cautions. For those managing both allergies and mental health conditions, a joined-up approach — involving the GP, pharmacist, and where relevant, a psychiatrist or allergy specialist — is considered best practice.

Ultimately, there is no need for people on antidepressants to go without effective allergy treatment. With appropriate guidance, the vast majority of allergic conditions can be managed safely and effectively. Open communication with healthcare professionals, combined with awareness of potential interactions and use of authoritative resources such as the NICE BNF, MHRA Drug Safety Updates, and individual SmPCs, is the cornerstone of safe prescribing and self-care in this context.

Frequently Asked Questions